The Italian breakthrough in CRISPR trials for rare diseases: a focus on beta-thalassemia and sickle cell disease treatment
Type One Von Willebrand - Search News
pharmaphorum6y Shire's von Willebrand disease therapy Veyvondi approved in EUThese include a phase 1 multicentre, controlled, randomised, single-blind, dose-escalation study of the safety, tolerability and pharmacokinectics in subjects 18 to 60 years of age with severe VWD.
Comments
Post a Comment